Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate at two upcoming CDMO industry conferences.  These include KNect365 Life Sciences’ BioProcess International West 2018, being held March 19-22, 2018 in San Francisco, CA, and DCAT Week 2018, being held March 19-22, 2018 in New York, NY.

Details of these activities are as follows:

KNect365 Life Sciences' BioProcess International West:

Avid will host corporate booth #415 showcasing the company’s comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services.  Company representatives will provide a virtual tour of Avid’s 40,000 square foot state-of-the-art commercial biomanufacturing suite (Myford facility).  The Myford facility is designed with cutting-edge, single-use equipment to accommodate a fully disposable biomanufacturing process.  A wide range of innovative features are incorporated into the facility including monolithic modular clean rooms, dedicated support utilities for each key processing area, and the industry’s most advanced single-use production systems and flexible solutions.  Uni-directional process flows separate personnel and materials and provide assurance that the design meets the most stringent regulatory requirements for commercial biologics API manufacturing.

DCAT Week:

Avid representatives will also be onsite at DCAT Week, an event hosted by the Drug, Chemical & Associated Technologies Association (DCAT).  In addition to participating in related networking events, the company is hosting a table at the DCAT Annual Dinner on Thursday, March 22.

For additional details on these events, please visit: https://lifesciences.knect365.com/bpi-west/ and https://dcatweek.org/.

About Avid Bioservices, Inc.Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture.  The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.  With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support.  The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.  www.avidbio.com

Contacts:
Kelly Pisarev Lord 
Avid Bioservices, Inc.
(800) 987-8256 

Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Avid Bioservices Charts.
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Avid Bioservices Charts.